# Phenex Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phenex-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Ludwigshafen, Germany
- Website: www.phenex-pharma.com
- Total disclosed funding: $19M
- Latest round: Series D (Oct 31, 2012)
- Investors on record: 6

## About

Phenex Pharmaceuticals AG is focused on developing innovative treatments for unmet medical needs in oncology and autoimmune diseases, targeting specific molecular pathways to improve therapeutic efficacy and minimize side effects.Founded in 2002 and headquartered in Ludwigshafen, Germany, Phenex Pharmaceuticals AG specializes in developing treatments for oncology and autoimmune diseases. The company has completed six deals, with the latest being a Series D funding round in which they raised EUR 5.000 mn from investors including CD-Venture, Creathor Ventures, and others. In January 2015, Gilead Sciences acquired Phenex's Farnesoid X Receptor (FXR) program for up to USD 470 million.Phenex Pharmaceuticals AG specializes in the development of innovative treatments aimed at addressing significant unmet medical needs within the realms of oncology and autoimmune diseases. The company's core product offerings revolve around novel pharmaceuticals that target specific molecular pathways to enhance therapeutic efficacy and minimize side effects. Notable products are designed to modulate immune responses or inhibit tumor growth, thereby providing targeted solutions for patients suffering from chronic conditions. The end users primarily include healthcare providers and patients in regions such as North America and Europe, where Phenex's products are actively marketed. The company focuses on maximizing patient outcomes through precision medicine, bridging the gap between scientific research and clinical application.Phenex Pharmaceuticals AG generates revenue through strategic collaborations and partnerships with other pharmaceutical entities, which facilitate the development and commercialization of its proprietary products. The company typically engages in B2B transactions, collaborating with larger biotech firms to leverage their distribution networks and market reach. A significant portion of revenue may also stem from milestone payments associated with the progression of clinical trials and regulatory approvals of its flagship products. The revenue model includes structured agreements that allow for co-development and profit-sharing, ensuring mutual benefits for Phenex and its partners. Pricing strategies are tailored to reflect the value delivered by their innovative therapies, aligning with industry standards for specialty pharmaceuticals targeted at specific patient populations.Phenex Pharmaceuticals AG aims to accelerate the development of its innovative therapies with the recent funding from the Series D round. The company plans to expand its product pipeline by introducing new treatments targeting specific cancer types and chronic autoimmune conditions, with anticipated launches in the next few years. Additionally, Phenex seeks to enter new markets across Asia and South America by 2025, leveraging its strategic partnerships to establish a strong presence. The funding from the most recent deal will support these initiatives, ensuring continued progress in its clinical programs and market expansion efforts.

## Funding rounds

- Series D, Oct 31, 2012, $6.3M — EVP Capital Management, KfW Banking Group, LBBW Venture Capital, Creathor Ventures, CD-Venture
- Series C, Sep 21, 2010, $7.7M — Swiss Life Asset Management, EVP Capital Management, KfW Banking Group, LBBW Venture Capital, Creathor Ventures, CD-Venture
- Series A, Oct 11, 2005, $5.1M — EVP Capital Management, KfW Banking Group

## Investors

- EVP Capital Management — Series A, Series C, Series D
- KfW Banking Group — Series A, Series C, Series D
- Swiss Life Asset Management — Series C
- LBBW Venture Capital (https://capitalatlas.ai/funds/lbbw-venture-capital) — Series C, Series D
- Creathor Ventures (https://capitalatlas.ai/funds/creathor-ventures) — Series C, Series D
- CD-Venture (https://capitalatlas.ai/funds/cd-venture) — Series C, Series D